FDANews

BASILEA REPORTS BAL8557 DATA

Basilea has reported data showing a favorable drug-drug interaction profile for BAL8557, its antifungal treatment.

The data show that BAL8557 has a promising drug-drug interaction profile. Ciclosporin and tacrolimus are frequently used and important immunosuppressant drugs in transplant medicine. BAL8557 had no significant impact on the pharmacokinetics of ciclosporin and a relatively modest effect on tacrolimus. In addition, BAL8557 did not affect the kinetics of warfarin, a widely used anticoagulant drug.